{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:07:08Z","timestamp":1791140828513,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ymgme.2009.11.005","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T02:42:04Z","timestamp":1259376124000},"page":"246-255","source":"Crossref","is-referenced-by-count":104,"title":["Treatment of mitochondrial electron transport chain disorders: A review of clinical trials over the past decade"],"prefix":"10.1016","volume":"99","author":[{"given":"Douglas S.","family":"Kerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2009.11.005_bib1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.bbadis.2008.10.015","article-title":"A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases","volume":"1792","author":"DiMauro","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2009.11.005_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.nurt.2008.07.002","article-title":"How can we treat mitochondrial encephalomyopathies? Approaches to therapy","volume":"5","author":"Horvath","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymgme.2009.11.005_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0091270003254637","article-title":"Efficacy of dichloroacetate as a lactate-lowering drug","volume":"43","author":"Stacpoole","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib4","first-page":"535","article-title":"Treatment of congenital lactic acidosis with dichloroacetate: a review","volume":"77","author":"Stacpoole","year":"1997","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.ymgme.2009.11.005_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2004.06.009","article-title":"Chronic treatment of mitochondrial disease patients with dichloroacetate","volume":"83","author":"Barshop","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.11.005_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0272-0590(90)90212-3","article-title":"Chronic toxicity of dichloroacetate: possible relation to thiamine deficiency in rats","volume":"14","author":"Stacpoole","year":"1990","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mus.1089","article-title":"Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate","volume":"24","author":"Spruijt","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2009.11.005_bib8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1542\/peds.2005-1226","article-title":"Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children","volume":"117","author":"Stacpoole","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.11.005_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1212\/WNL.50.2.531","article-title":"Effects of dichloroacetate in three patients with MELAS","volume":"50","author":"Saitoh","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.11.005_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.braindev.2003.12.009","article-title":"Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS","volume":"26","author":"Mori","year":"2004","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymgme.2009.11.005_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/01.wnl.0000196641.05913.27","article-title":"Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial","volume":"66","author":"Kaufmann","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.11.005_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.clnu.2008.05.007","article-title":"New indications and controversies in arginine therapy","volume":"27","author":"Coman","year":"2008","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ymgme.2009.11.005_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/01.WNL.0000151976.60624.01","article-title":"L-arginine improves the symptoms of stroke like episodes in MELAS","volume":"64","author":"Koga","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.11.005_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/01.wnl.0000220197.36849.1e","article-title":"Endothelial dysfunction in MELAS improved by L-arginine supplementation","volume":"66","author":"Koga","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.11.005_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.mito.2006.11.006","article-title":"MELAS and L-arginine therapy","volume":"7","author":"Koga","year":"2007","journal-title":"Mitochondrion"},{"key":"10.1016\/j.ymgme.2009.11.005_bib16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0891-5849(98)00077-X","article-title":"The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria","volume":"25","author":"Shivaram","year":"1998","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ymgme.2009.11.005_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biof.5520320113","article-title":"Human CoQ10 deficiencies","volume":"32","author":"Quinzii","year":"2008","journal-title":"Biofactors"},{"key":"10.1016\/j.ymgme.2009.11.005_bib18","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1073\/pnas.81.11.3529","article-title":"31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle","volume":"81","author":"Eleff","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2009.11.005_bib19","unstructured":"P. W. Stacpoole, T.J. deGrauw, A.S. Feigenbaum, D.S. Kerr, Phase III Trial of Coenzyme Q10 in Mitochondrial Disease; www.clinicaltrials.gov, NCT00432744 (2009)."},{"key":"10.1016\/j.ymgme.2009.11.005_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2005.11.004","article-title":"Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial","volume":"35","author":"Miles","year":"2006","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib21","unstructured":"P. Kaufmann, M. Hirano, Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes (MELAS); www.clinicaltrials.gov, NCT00887562 (2009)."},{"key":"10.1016\/j.ymgme.2009.11.005_bib22","unstructured":"J. Rouleau, T. Klopstock, P.F. Chinnery, Study to Assess Efficacy, Safety and Tolerability of Idebenone for Leber\u2019s Hereditary Optic Neuropathy; www.clinicaltrials.gov, NCT00747487 (2009)."},{"key":"10.1016\/j.ymgme.2009.11.005_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","article-title":"Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions","volume":"291","author":"Schapira","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2009.11.005_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/biof.5520250113","article-title":"Clinical trials of coenzyme Q10 in neurological disorders","volume":"25","author":"Shults","year":"2005","journal-title":"Biofactors"},{"key":"10.1016\/j.ymgme.2009.11.005_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.expneurol.2004.05.003","article-title":"Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson\u2019s disease","volume":"188","author":"Shults","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib27","doi-asserted-by":"crossref","unstructured":"NINDS NET-PD Investigators, A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease, Neurology 68 (2007) 20\u201328.","DOI":"10.1212\/01.wnl.0000250355.28474.8e"},{"key":"10.1016\/j.ymgme.2009.11.005_bib28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","article-title":"Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease","volume":"64","author":"Storch","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib29","unstructured":"M.F. Beal, D. Oakes, I. Shoulson, Effects of Coenzme Q10 (CoQ) in Parkinson Disease; www.clinicaltrials.gov, NCT007407140 (2009)."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2009.11.005_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00415-009-1003-2","article-title":"The pathogenesis of Friedreich ataxia and the structure and function of frataxin","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2009.11.005_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00415-009-1008-x","article-title":"Clinical experience with high-dose idebenone in Friedreich ataxia","volume":"256","author":"Schulz","year":"2009","journal-title":"J. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2009.11.005_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00415-009-1005-0","article-title":"Idebenone: an emerging therapy for Friedreich ataxia","volume":"256","author":"Meier","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archneur.64.6.803","article-title":"Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia","volume":"64","author":"Di Prospero","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Di Prospero","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib35","unstructured":"S. Perlman, D. Lynch, Study of the Efficacy, Safety, and Tolerability of Idebenone in the Treatment of Friedreich\u2019s Ataxia; www.clinicaltrials.gov: NCT00537680 (2009)."},{"key":"10.1016\/j.ymgme.2009.11.005_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ana.1050","article-title":"Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects","volume":"50","author":"Taivassalo","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2009.11.005_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/brain\/awg028","article-title":"The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients","volume":"126","author":"Taivassalo","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2009.11.005_bib38","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/brain\/awl282","article-title":"Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions","volume":"129","author":"Taivassalo","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2009.11.005_bib39","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/brain\/awl149","article-title":"Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy","volume":"129","author":"Jeppesen","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2009.11.005_bib40","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1093\/brain\/awn252","article-title":"Taivassalo. Resistance training in patients with single, large-scale deletions of mitochondrial DNA","volume":"131","author":"Murphy","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2009.11.005_bib41","unstructured":"R. G. Haller. The Effects of Exercise vs. Inactivity on People with Mitochondrial Muscle Diseases; www.clinicaltrials.gov, NCT00457314 (2009)."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209004879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209004879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T00:52:19Z","timestamp":1544835139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719209004879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1096719209004879"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2009.11.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}